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Abstract
Background: Postoperative ventricular dysfunction (VnD) occurs in 9–20% of coronary artery bypass graft (CABG) surgical
patients and is associated with increased postoperative morbidity and mortality. Understanding genetic causes of
postoperative VnD should enhance patient risk stratification and improve treatment and prevention strategies. We aimed to
determine if genetic variants associate with occurrence of in-hospital VnD after CABG surgery.
Methods: A genome-wide association study identified single nucleotide polymorphisms (SNPs) associated with
postoperative VnD in male subjects of European ancestry undergoing isolated primary CABG surgery with cardiopulmonary
bypass. VnD was defined as the need for $2 inotropes or mechanical ventricular support after CABG surgery. Validated SNPs
were assessed further in two replication CABG cohorts and meta-analysis was performed.
Results: Over 100 SNPs were associated with VnD (P,10
24), with one SNP (rs17691914) encoded at 3p22.3 reaching
genome-wide significance (Padditive model=2.14610
28). Meta-analysis of validation and replication study data for 17 SNPs
identified three SNPs associated with increased risk for developing postoperative VnD after adjusting for clinical risk factors.
These SNPs are located at 3p22.3 (rs17691914, ORadditive model=2.01, P=0.0002), 3p14.2 (rs17061085, ORadditive model=1.70,
P=0.0001) and 11q23.2 (rs12279572, ORrecessive model=2.19, P=0.001).
Conclusions: No SNPs were consistently associated with strong risk (ORadditive model.2.1) of developing in-hospital VnD after
CABG surgery. However, three genetic loci identified by meta-analysis were more modestly associated with development of
postoperative VnD. Studies of larger cohorts to assess these loci as well as to define other genetic mechanisms and related
biology that link genetic variants to postoperative ventricular dysfunction are warranted.
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Each year almost 250,000 patients undergo coronary artery
bypass graft (CABG) surgery in the United States alone, with the
primary aim of surgery being to prevent major adverse
cardiovascular events [1]. Despite the goal of improving health,
9–20% of patients undergoing cardiac surgery develop in-hospital
postoperative ventricular dysfunction (VnD; defined as a new
requirement for $2 inotropes or placement of an intra-aortic
balloon pump or ventricular assist device), an outcome which is
associated with significantly increased postoperative morbidity and
mortality [2,3,4,5]. Clinical predictors such as preoperative left
ventricular ejection fraction (LVEF) and duration of cardiopul-
monary bypass (CPB) explain only ,20% of variability in
occurrence of VnD after coronary artery bypass graft (CABG)
surgery [6]. Given evidence for genetic influences on cardiac
dysfunction, we therefore hypothesize that common genetic
variants contribute to the development of postoperative VnD
[6,7].
We have previously examined candidate genetic loci and have
identified single nucleotide polymorphisms (SNPs) within the
NPPA/NPPB and NPR3 natriuretic peptide system genes that
associate with VnD after CABG surgery with adjusted odds ratios
for association .2.0 [6]. However, to provide an unbiased
assessment for common genetic variants that contribute strongly to
this phenotype, we now have conducted an exploratory genome-
wide association study (GWAS) of patients undergoing primary
CABG surgery with CPB. From this GWAS we further assessed
validated SNPs associated with VnD in two replication CABG
cohorts and also conducted corresponding meta-analyses. Identi-
fication of novel genetic loci associated with VnD after CABG
surgery provides the foundation from which to define causal genes
and related molecular mechanisms. Such understanding may
ultimately mitigate incidence of postoperative heart failure by
suggesting new therapeutic opportunities for its prevention and
treatment and by improving surgical risk stratification.
Methods
Study Subjects
Ethics Statement: In compliance with the Declaration of
Helsinki, respective Institutional Review Board approval and
subject written informed consent were obtained for all subjects
(Partners Institutional Review Board, Boston, MA, USA; St.
Luke’s Episcopal Hospital Institutional Review Board, Houston,
TX, USA; Vanderbilt University Institutional Review Board
overseen by the Vanderbilt University Human Research Protec-
tion Program, Nashville, TN, USA).
Data were collected prospectively from primary CABG
surgical patients at three institutions: Brigham and Women’s
Hospital (BWH; Boston, MA), the Texas Heart Institute (THI;
Houston, TX), and Vanderbilt University Medical Center
(Nashville, TN). These institutions enrolled subjects into two
cardiac surgical cohorts: the CABG Genomics Program (BWH
and THI) and the Vanderbilt Cardiac Surgery Registry (VCSR).
De-identified control genotypes were provided for the GWAS
from an ambulatory multiple sclerosis study cohort of European
ancestry subjects. Information S1 further describes the study
cohorts.
CABG subjects were prospectively excluded from analyses if
they had emergency surgery, re-operative cardiac surgery,
concurrent valve surgery, no aortic cross-clamp, or CPB
.220 minutes, or if preoperatively they had moderate to severe
mitral regurgitation, LVEF ,20%, severe preoperative renal
dysfunction (hemodialysis or serum creatinine .3 mg/dL), or
were receiving inotrope, intra-aortic balloon pump or ventricular
assist device support. To minimize false positive SNP associations
related to population stratification, all analyses were restricted to
European ancestry subjects. With the exception of the GWAS’
controls, analyses did not include women, as gender may influence
development of heart failure, and the number of female subjects
with VnD enrolled in the CABG Genomics and VCSR cohorts
(,20%) was insufficient to support gender stratified SNP
association analyses [5,8,9].
Postoperative VnD cases were identified in accordance with
prior studies [3,6,10], with the VnD phenotype defined as a new
requirement for $2 inotropes, or new placement of an intra-aortic
balloon pump or ventricular assist device either during the
intraoperative period after the patient separated from CPB or
postoperatively in the intensive care unit. Since postoperative
intensive care unit data was not obtained for VCSR subjects, VnD
was assessed using intra-operative criteria for this cohort. Inotrope
support was defined as continuous infusion of amrinone,
milrinone, dobutamine, dopamine (.5 mcg/kg/min), epineph-
rine, isoproterenol, norepinephrine, or vasopressin.
Genotyping
Genomic Arrays. Genotypes were ascertained using the
Affymetrix 6.0 Genome-Wide Human SNP Array (Affymetrix,
Santa Clara, CA) and were analyzed using the Birdseed (version 2)
algorithm. SNPs were excluded from analyses for call rates ,95%,
minor allele frequencies ,1%, or for not exhibiting Hardy
Weinberg equilibrium (P,10
26). SNPs were also excluded if they
had a plate association (P,10
210) or differential missingness either
between cases and controls (P,0.001) or based on flanking
haplotypes (P,10
210; flanking haplotypes consisted of the 2 SNPs
that were the closest adjacent Array SNPs upstream and downs-
tream of the assessed SNP).
Individual SNP Genotypes. Genotypes were determined
using Sequenom MassArray iPLEXH (Sequenom, San Diego, CA)
and the manufacturer’s protocols. Sequenom raw data were
analyzed with the SpectroTyper 3.4 software (Sequenom, San
Diego, CA). Spectra and cluster plots were checked by visual
inspection of intensity plots with manual curation of genotype
calls.
Statistical Analyses
Genome-Wide Association Study. Subjects were excluded
from GWAS analyses if they did not self-identify to be of European
ancestry. In addition, population stratification outliers were
excluded from GWAS analyses as described in Information S1,
and multidimensional scaling analysis was used to provide further
reassurance that population stratification did not influence GWAS
association results [11]. GWAS data was assessed using PLINK
(version 1.07) [11].
Because the cohort size of this exploratory study would detect
only genetic variants with strong associations with development of
postoperative VnD, a Type 1 error rate ,0.0005 was utilized for
statistical power assessments. This P value threshold was chosen
with the understanding that a proportion of SNP associations
detected at this level of significance could be false positive
associations and that further assessment would be conducted
beyond the initial GWAS. Based on the available case to control
ratio of 1:14 and assuming an additive genetic model, 12%
incidence of VnD, 80% power, minimum estimated detectable
genetic risk ratios for the GWAS were 2.1, 2.2, 2.3, 2.5, and 2.8 for
SNPs with minor allele frequencies of .0.25, 0.25, 0.20, 0.15, and
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frequencies ,5% were not analyzed for association with VnD.
Association between SNPs and VnD were estimated using the
trend test for the additive genetic model, the Pearson chi-square
test for allelic and dominant genetic models, and the Fisher’s
Exact test for the recessive genetic model. Using genomic
inflation factor lambdas genomic-control corrections were made
to account for residual population stratification effects suggested
by Q-Q plots (Figure S1). Cluster plots (Figure S2) for SNPs
associated with VnD were visually inspected and SNPs with poor
differentiation of heterozygote and homozygote calls were
eliminated.
Validation and Replication Studies. Categorical and con-
tinuous patient demographic and clinical characteristics were
compared between case and control groups for the CABG
Genomics validation study, Vanderbilt replication study, and
CABG Genomics replication study using Pearson’s chi-squared,
Fisher’s Exact or student’s t-tests where appropriate ( JMP version
7.0.1, SAS Institute, Cary, NC). PLINK (version 1.07) was used
for genetic analyses [11]. Hardy Weinberg Equilibrium was
evaluated using Fisher’s Exact tests.
Univariate SNP associations with VnD were assessed using
Pearson chi-square tests for the allelic model and logistic
regression for the additive, dominant and recessive models.
SNP associations (additive, dominant and recessive models) were
additionally adjusted for age, LVEF, CPB time, and institution
using logistic regression. Univariate and multivariable adjusted
odds ratios (OR) and 95% confidence intervals (CI) were
determined for each SNP. Point-wise permutation analyses
(10,000 rounds of permuting case/control status for each genetic
model) were conducted for each SNP (univariate and multivar-
iable covariate adjusted assessments). In order to assess that
observed SNP associations with VnD were not a consequence of
associations with presenting LVEF, linear regression was used to
conduct univariate assessments of CABG Genomics validation
study SNPs for association with preoperative LVEF. Meta-
analyses were conducted for SNPs successfully genotyped for both
replication studies (methods described in Information S1).
Bonferroni adjustments were applied to analyses to correct for
multiple SNP tests.
Results
We performed a GWAS study that compared CABG Genomics
cases with ambulatory control subjects. Validated SNPs associated
with VnD in the GWAS study were further assessed using CABG
Genomics control subjects. SNPs from this analysis were then
evaluated in replication studies of the CABG Genomics and
VCSR cohorts, and related meta-analyses were performed
(Figure 1).
Demographic and clinical characteristics for the study cohorts
are shown in Table 1. Although gender was the only demographic
information available for the multiple sclerosis study cohort, these
subjects only provided the control genotype data used in the
GWAS analyses.
As expected there were significant differences in the clinical
characteristics of CABG subjects with and without VnD (cases and
controls, respectively). All VnD cases had significantly lower
preoperative LVEFs and longer CPB times than CABG controls
(P,0.05), and CABG Genomics cases used for validation had
more subjects with a .30 pack year history of smoking than
CABG controls (P,0.05). VnD cases assessed in validation and
replication studies differed significantly between groups with
regards to preoperative LVEF, but not other characteristics.
Genome-Wide Association Study
We surveyed the genomes of 92 male VnD cases using
Affymetrix 6.0 arrays. Sixteen samples were subsequently excluded
from analysis based upon genotyping quality control, gender
mismatch, population stratification outliers, and cryptic related-
ness (methods described in Information S1). Applying these same
filters, 1123 ambulatory controls (28% male) were appropriate to
be studied from the multiple sclerosis study cohort. Based on these
cohort sizes, this GWAS was powered to detect genetic risk ratios
$2.1.
Analyses of 709,355 SNPs identified 123 SNPs (63 genetic loci)
thatwereassociated with VnD with P values,10
24 (TableS1). One
SNP, rs17691914, reached genome-wide significance by allelic
(P=3.4610
28) and additive models (P=2.1610
28). This SNP had
minor allele frequencies of 21% and 7% in VnD cases versus
controls, respectively. An additional 10 SNPs associated with VnD
with P values ,10
25. Three of these 10 SNPs (rs9835451,
rs1979406, and rs17032625) reside within the same chromosome 3
locus as rs17691914 (chromosome 3: 34,902,008–35,052,013 bp).
Of the SNPs with P values ,10
25, rs2171325 was not assessed in
further validation or replication studies because the minor allele
frequency was ,10% in both cases and controls. Figure 2 shows
allelic model results for association with VnD across all 22
autosomes.
CABG Genomics Technical Validation and CABG Control
Studies
GWAS SNPs with a minor allele frequency.10% and P,10
24
for association with VnD (after genomic-control corrections for
allelic, additive, dominant and recessive genetic models) were
selected for further assessment in CABG Genomics cases and
controls. Five samples that failed $90% of validation study
genotyping and one SNP (rs11060480) that did not technically
validate were excluded from further study. After clinical and
genotyping exclusions, data for 71 of the 76 GWAS VnD cases
and 715 male CABG controls (subjects without VnD) were
analyzed. The technical validation aspect of this study compared
minor allele frequencies for the VnD cases for Affymetrix 6.0
versus Sequenom genotyping in order to identify potential false
positive GWAS associations due to technical calling errors. In
addition, this study refined the initial genetic association study in
order to: 1) assess if GWAS associations persisted when the VnD
case data was compared to male CABG control data; 2) allow
assessment of additional SNPs with moderate linkage disequilib-
rium with identified GWAS SNPs (correlation r
2 with GWAS
SNPs=0.30–0.70) in order to identify SNPs within GWAS loci
with potentially stronger associations with VnD; 3) allow covariate
adjustment of SNP associations for age, institution, LVEF and
duration of CPB; 4) allow assessment of SNP associations with
preoperative LVEF.
Sixty-three SNPs (36 GWAS SNPs and 27 SNPs in linkage
disequilibrium with these SNPs) were assessed in 71 VnD cases
and 715 CABG controls (Table S2). Twenty-two SNPs encoded at
15 loci had both asymptotic and point-wise permuted univariate P
values #0.0005, and we selected 19 of these SNPs for further
exploration in replication studies (Table 2). After Bonferroni
correction, none of these SNPs showed significant association with
preoperative LVEF, the primary clinical predictor of VnD [6].
Replication Studies
The 19 SNPs selected for replication were assessed initially in
the VCSR cohort. Two SNPs, rs9837024 and rs10773689, were
excluded due to failed genotyping and Hardy Weinberg
GWAS of Ventricular Dysfunction after CABG Surgery
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remaining 17 SNPs (encoded at 13 loci) are shown in Table S3.
For 10 SNPs (encoded at 7 loci) the direction of the ORs was
consistent across the GWAS, validation, and VCSR replication
studies, but only rs17061085 associated with VnD with P,0.05
(unadjusted ORadditive model=1.65, P=0.04; covariate adjusted
ORadditive model=1.69, P=0.056). This association is not signifi-
cant after Bonferroni adjustment.
We also assessed replication in the CABG Genomics cohort using
previously unstudied cases. All 19 SNPswere successfully genotyped,
and for 12 SNPs (encoded at 10 loci), the direction of the ORs was
consistent across the GWAS and validation studies. However, none
ofthese 12SNPsachieved significant association with VnD(P,0.05)
in univariate or multivariable adjusted analyses (Table S4).
Meta-analyses
To assess for more modest risk (OR ,2.1) that might be
associated with putative VnD SNPs, we performed a meta-analysis
of the VCSR and CABG Genomics cohort replication studies.
SNP rs17061085 was associated with postoperative VnD with the
same direction of effect as the GWAS, even after adjusting for
age, preoperative LVEF and CPB time (OR=1.44, P=0.04,
Cochrane Q statistic test for heterogeneity P=0.47 and I
2
heterogeneity index=0). However, this association does not
achieve statistical significance after Bonferroni adjustment.
In order to identify SNPs with the strongest associations with
VnD within the overall group of CABG subjects assessed in this
study, we also pooled all VnD case (n=188) and non-VnD CABG
control (n=1200) data from the validation and replication studies
Figure 1. Schematic illustrating sequence of GWAS study followed by validation study, replication studies, and meta-analysis. All
subjects were of European ancestry and were male unless otherwise specified. * 39 Affymetrix 6.0 SNPs associated with VnD in the GWAS (P,10
24)o r
SNPs in strong linkage disequilibrium (r
2.0.80; estimated using HaploView 4.1.) with these GWAS SNPs were genotyped from 34 genetic loci for
further validation study assessment. { In order to identify SNPs with potentially stronger associations with VnD within some of the genetic loci
identified in the GWAS, additional SNPs were genotyped that were in moderate linkage disequilibrium with associated GWAS SNPs (r
2=0.30–0.70).
Correlations (r
2) were estimated using HaploView 4.1.
{ SNP associations with VnD were analyzed by enrolling institution (BWH, THI, and Vanderbilt
University Medical Center) with adjustments for age, preoperative LVEF, and duration of CPB time, and then combined by meta-analysis.
doi:10.1371/journal.pone.0024593.g001
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(rs17691914, rs17061085, and rs12279572) having the smallest P
values (P#0.001) for association with VnD after adjusting for age,
preoperative LVEF and duration of CPB.
Discussion
VnD after cardiac surgery is associated with significant patient
morbidity and mortality. Although clinical parameters such as
preoperative LVEF and duration of CPB are predictive of risk for
developing postoperative VnD [3,5], other unknown factors are
expected to contribute to postoperative cardiac dysfunction. Using
genome-wide assessments, we defined 3 novel genetic variants
(rs17691914 on 3p22.3; rs17061085 on 3p14.2; rs12279572 on
11q23.2) that associate with development of VnD after primary
CABG surgery, even after adjusting for age, preoperative LVEF,
and prolonged CPB time. These data suggest genetic risk as a
contributor to cardiac dysfunction that occurs in the setting of
CABG and presumably other overt myocardial stresses.
Future study of the genes at the 3 loci tagged by these VnD-
associated SNPs may enhance understanding of the pathophysi-
ology of postoperative VnD. The 3p22.3 locus (defined by
rs17691914) is located within 1 Mb of the programmed cell death
6-interacting protein gene (PDCD6IP). Despite a paucity of other
Table 1. Study cohort characteristics of cases and controls undergoing primary coronary artery bypass grafting with
cardiopulmonary bypass.
Subject Group (number of subjects) Age years BMI kg/m
2 Diabetes Hypertension
Smoking
.30 pyh LVEF %
CPB time
minutes
CABG Genomics validation cases (n=71)* 65611 3065 35.2% 74.6% 45.5%
{ 42614
{1 112634
{
CABG Genomics validation controls (n=715)
{ 64610 3065 25.9% 72.7% 29.6%
{ 54611
{ 93634
{
CABG Genomics replication cases (n=59) 64693 0 67 30.5% 71.2% 38.5% 49615
{1 102637
{
CABG Genomics replication controls (n=921)
{ 63610 3066 26.3% 73.9% 29.3% 54611
{ 92635
{
Vanderbilt replication cases (n=58) 63611 2965 38.6% 71.9% 46.6% 35613
{1 113634
{
Vanderbilt replication controls (n=279) 61610 2965 32.0% 74.9% 39.9% 4868
{ 110630
{
Data shown as (%) for dichotomous variables and mean 6 standard deviation for continuous variables.
BMI=body mass index; CPB=cardiopulmonary bypass; LVEF=left ventricular ejection fraction; pyh=pack year history; SNP=single nucleotide polymorphism.
*Genome-wide association study assessed 76 ventricular dysfunction cases; subsequent SNP analyses were successfully validated for 71 of these ventricular dysfunction
cases.
{CABG Genomics replication controls include control subjects used in the CABG Genomics validation study.
{Significantly different between cases and controls (P,0.05).
1Significantly different than other two case groups (P,0.05).
doi:10.1371/journal.pone.0024593.t001
Figure 2. The –log P value (lambda adjusted) of the allelic genetic model for each single nucleotide polymorphism (SNP) according
to location on the 22 autosomal chromosomes. Horizontal line indicates the 5610
28 P value threshold for genome-wide significance.
doi:10.1371/journal.pone.0024593.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24593genes within close proximity to rs17691914, we are intrigued that
this SNP achieved genome-wide significance in the initial GWAS
and that the 3p22.3 is also tagged by a SNP (rs12638540) within
an intron of the CKLF-like MARVEL transmembrane domain
containing 7 gene (CMTM7) that is reported to be significantly
associated with heart failure mortality (Hazard Ratio=1.53;
P=3.21610
27) in a GWAS meta-analysis of 2,526 ambulatory
patients [13]. An interesting possibility is that these 3p22.3 SNPs
are linked to a single causal gene that impacts cardiac function.
SNP rs17061085, which maps to 3p14.2, resides near the fragile
histidine triad (FHIT) gene that encodes a protein implicated in
multiple cancers [14]. While FHIT has not been well studied in
cardiac tissue, human atrial expression of FHIT is diminished in
the setting of decreased LVEF [15].
The 11p11.2 intronic SNP rs12279572 lies within the
TMPRSS4 (transmembrane protease, serine 4 isoform-1) gene that
encodes a protein implicated in facilitating the invasion, migration
and metastasis of human tumor cells via epithelial-mesenchymal
transitions [16]. This protein has unknown relevance to cardiac
biology. Twelve other known genes are encoded within 250 kbps
of SNP rs12279572. These include genes encoding interleukin-10
receptor A (IL10RA), which may participate in the oxidative-stress
responses that promote cardiac remodeling and heart failure [17],
and 2 sodium channel subunits (SCN4B and SCN2B) that are
expressed in cardiac myocytes and are mutated in long-QT
syndrome and atrial fibrillation, respectively [18,19].
Limitations
We recognize several important limitations of our study,
including the small size of the study cohorts and the narrow
demographic profiles we were consequently able to examine. We
consider this study to be an exploratory assessment for strong
genetic influences on the postoperative ventricular dysfunction
outcome, as cohort size restricted our ability to detect SNPs
associated with VnD with genetic risk ratios ,2.1 for an additive
genetic model. We secondarily assessed dominant and recessive
genetic models, albeit with statistical power to detect substantially
higher genetic risk ratios for these models than for the additive
model. Our findings have important implications for design of
future studies, in that no SNPs consistently associated with
postoperative VnD with additive model ORs .2.1. However,
GWASs of cardiovascular disease in very large non-surgical
populations illustrate the potential to discover SNPs associated
with more modest risks of developing common disease. For
example, loci found to be associated with coronary artery disease
and/or myocardial infarction [20,21,22,23] in large ambulatory
GWAS assessments reported lower ORs (additive model ORs of
1.10–1.65) than those achieved here. As such we expect that
assessments of postoperative VnD in larger surgical cohorts will be
needed to define loci with more modest associations with this
phenotype.
We recognize that gaps in the Affymetrix 6.0 Genome-Wide
array may still potentially miss important SNP associations with
VnD, as all commercially available genome-wide SNP arrays have
some gaps in coverage of genetic variability across the genome
[24]. For example, we previously identified SNPs within the
NPPA/NPPB gene complex on chromosome 1 that significantly
associate with VnD after CABG surgery (additive model ORs
1.85–2.29)[6]; yet, these NPPA/NPPB SNPs were not assessed in
the Affymetrix 6.0 SNP array platform. However, the Affymetrix
6.0 Genome-Wide array is estimated to cover ,83% of genome-
wide SNP variability, thus providing very good potential for this
study to detect novel SNP associations with VnD after CABG
surgery [24].
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24593Another important limitation of this study was the narrow
demographic profile of the analyzed study cohorts. There were not
enough women enrolled within the CABG Genomics and VCSR
cohorts to allow for SNP association analyses stratified by gender.
Nor were there sufficient non-European ancestry subjects of either
gender to allow for SNP association analyses stratified by ethnicity.
Limiting this study to men of European ancestry enhanced
homogeneity of the study cohort for the purpose of best allowing
detection of real SNP associations with VnD that were not
confounded by influence of gender and racial background.
However, we therefore propose that further evaluations of VnD-
associated SNPs be conducted in women and in both men and
women of non-European ancestry when cohorts are available that
contain sufficient sample sizes of these populations.
Conclusions
In conclusion, at least 3 loci identified by genome-wide and
subsequent validation and replication assessments were associated
with modest risk for VnD after primary CABG surgery. These and
other SNPs within the surrounding genetic loci warrant further
replication in large cardiac surgical cohorts. With continued
identification of genotypes associated with postoperative VnD, we
expect to improve risk stratification and gain insights into biologic
pathways linking these variants to postoperative myocardial
dysfunction. Such knowledge could lead to new preventions and
therapies for postoperative VnD, and, possibly other forms of
heart failure.
Supporting Information
Figure S1 Genome wide association study Q-Q plots of
the expected and observed –log P values for SNP
associations with ventricular dysfunction after primary
coronary artery bypass graft surgery. Genomic inflation
factor lambdas derived from these Q-Q plots were used to adjust
GWAS association findings for potential population stratification:
allelic model lambda=1.08, additive model (trend test) lamb-
da=1.07, dominant model lambda=1.05, and recessive model
lambda=1.00.
(TIF)
Figure S2 Examples of single nucleotide polymorphism
(SNP) genotyping cluster plots with good and poor
differentiation between heterozygotes and homozygotes.
SNP=single nucleotide polymorphism; NC=no genotype call;
AA=homozygote genotype for one allele; AB=heterozygote
genotype call; BB homozygote genotype call for other allele Two
investigators visually inspected intensity cluster plots for genotyping
calls for those SNPs with GC adjusted association P val-
ues,1.0610
24 in the GWAS (allelic, additive and dominant
model). Intensity cluster plots for recessive model SNPs with
association GC adjusted P values,10
25 in the GWAS as
determined by chi-square tests were also reviewed, and P values
for SNPs with good cluster plot differentiation were then assessed
using Fisher’s exact tests (SNPs with P,10
24 by Fisher’s Exact tests;
Table S1). Cluster plots were categorized as having good or poor
differentiation between homozygote and heterozygote calls (plots
were derived from GWAS Affymetrix 6.0 Genome-Wide Human
SNP Array case and control data called together using Birdseed
version 2 calling algorithm). SNPs with poorly differentiated
intensity cluster plots were dropped from further consideration in
validation and replication studies (33 SNPs for allelic model, 35
SNPs additive model, 24 SNPs for recessive model). The X axis
represents contrast ([A2B]/[A+B]), and the Y axis represents
strength (log[A+B]), where A and B are the summarized intensities
of the two alleles for one sample. Summarized intensities means a
single value that summarizes the intensities of all the many
oligonucleotide probes on the chip that contribute to measuring
this binary allele at this SNP locus.
(TIF)
Information S1 Supplementary Methods.
(DOC)
Table S1 Genome wide association study results: SNP
associations with ventricular dysfunction after primary
coronary artery bypass graft surgery.
(DOC)
Table S2 Validation study results: SNP associations
with ventricular dysfunction after primary coronary
artery bypass graft surgery in 786 European ancestry
men from the CABG Genomics Study Cohort. 63 SNPs
were selected from 34 genetic loci identified to be associated with
ventricular dysfunction in the GWAS.
(PDF)
Table S3 Vanderbilt cohort replication study results: 17
SNP associations (13 genetic loci) with ventricular
dysfunction after primary coronary artery bypass graft
surgery in 337 European ancestry men.
(DOC)
Table S4 CABG Genomics cohort replication study
results: 19 SNP associations (15 genetic loci) with
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